SYNTHESIS OF NOVEL DRUGS OF P38 KINASE INHIBITOR

Mithilesh Singh*, Sonu Sharma and Dr. Ashish K. Sharma

ABSTRACT

The MAP kinase p38 has been implicated in cytokine signaling, and its inhibitors are potentially useful for the treatment of arthritis and osteoporosis. Novel small-molecule inhibitors of p38 kinase were derived from a combinatorial chemistry effort. The p38 protein kinase is a serine-threonine mitogen activated protein kinase, which plays an important role in inflammation and arthritis. Many p38α inhibitors with diverse chemical structures and modes of protein interaction have been designed on the basis of their ability to compete with ATP site or Allosteric site for binding to p38α. In the late 1970’s and early 1980’s the initial p38 chemo type, triaryl imidazole was discovered. During the last ten years a number of novel p38 chemotypes were discovered via high through put screening. A step has been taken forward to give a little contribution in the synthesis of p38 kinase inhibitors to make it more effective.

Keywords: MAPK, p38 kinase, allosteric site.